Barclays Keeps Their Buy Rating on PTC Therapeutics (PTCT)
TipRanks (Mon, 3-Aug 4:45 AM ET)
PTC Therapeutics (PTCT) Gets a Buy from Cantor Fitzgerald
TipRanks (Fri, 31-Jul 11:47 AM ET)
PTC Therapeutics (PTCT) Gets a Hold from RBC Capital
TipRanks (Fri, 31-Jul 10:47 AM ET)
TipRanks (Fri, 31-Jul 8:40 AM ET)
Morgan Stanley Keeps Their Buy Rating on PTC Therapeutics (PTCT)
TipRanks (Fri, 31-Jul 7:27 AM ET)
Analysts Are Bullish on These Healthcare Stocks: PTC Therapeutics (PTCT), Guardant Health (GH)
TipRanks (Fri, 31-Jul 7:00 AM ET)
Wells Fargo Sticks to Their Buy Rating for PTC Therapeutics (PTCT)
TipRanks (Fri, 31-Jul 6:36 AM ET)
Analysts’ Top Healthcare Picks: PTC Therapeutics (PTCT), Arrowhead Pharmaceuticals (ARWR)
TipRanks (Thu, 30-Jul 9:50 PM ET)
PTC Therapeutics Raises Outlook on Strong Q2 Results
TipRanks (Thu, 30-Jul 5:14 PM ET)
PTC Therapeutics GAAP EPS of $0.92 beats by $0.71, revenue of $360.5M beats by $61.87M
Seeking Alpha News (Thu, 30-Jul 4:05 PM ET)
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
PTC Therapeutics trades on the NASDAQ stock market under the symbol PTCT.
As of August 4, 2026, PTCT stock price climbed to $69.05 with 313,656 million shares trading.
PTCT has a beta of 0.49, meaning it tends to be less sensitive to market movements. PTCT has a correlation of 0.02 to the broad based SPY ETF.
PTCT has a market cap of $5.76 billion. This is considered a Mid Cap stock.
Last quarter PTC Therapeutics reported $361 million in Revenue and $.92 earnings per share. This beat revenue expectation by $68 million and exceeded earnings estimates by $.61.
In the last 3 years, PTCT traded as high as $90.87 and as low as $17.53.
The top ETF exchange traded funds that PTCT belongs to (by Net Assets): IJR, VTI, VB, IWM, XBI.
PTCT has outperformed the market in the last year with a return of +32.5%, while the SPY ETF gained +24.6%. However, in the most recent history, PTCT shares have underperformed the stock market with its stock returning +6.0% in the last 3 month period and -11.5% for the last 2 week period, while SPY has returned +6.7% and +3.4%, respectively.
PTCT support price is $66.21 and resistance is $70.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PTCT shares will trade within this expected range on the day.